Bravigo: Dosing, Side Effect & Interaction

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Ivabradine HCl

Indications/Uses

Symptomatic stable angina pectoris in adults whose heart rate is ≥70 bpm & who do not tolerate or cannot take β-blockers, or in combination w/ β-blockers in adults whose condition is not fully controlled w/ a β-blocker. Chronic heart failure in adults whose heart rate is ≥75 bpm in combination w/ standard therapy, including β-blocker therapy, or when β-blockers are contraindicated or not tolerated.

Click to view Bravigo detailed prescribing information

Dosage/Direction for Use

Patient <75 yr Initially 5 mg bd, may be increased to 7.5 mg bd (1 tab in the morning & 1 tab in the evening), ≥75 yr 2.5 mg bd (½ of 5-mg tab in the morning & ½ of 5-mg tab in the evening).

Click to view Bravigo detailed prescribing information

Overdosage

View Bravigo overdosage for action to be taken in the event of an overdose.

Administration

Should be taken with food.

Contraindications

Hypersensitivity. Concomitant use w/ ketoconazole, itraconazole, josamycin, clarithromycin, telithromycin, oral erythromycin, nelfinavir, ritonavir, nefazodone, verapamil, diltiazem. Patients w/ resting heart rate <70 bpm before treatment; cardiogenic shock; sick sinus syndrome, SA block, 3rd degree AV block; heart attack; very low BP; unstable angina; worsening heart failure; heartbeat exclusively imposed by pacemaker; severe liver problems. Women of childbearing potential not using reliable contraception. Pregnancy & lactation.

Click to view Bravigo detailed prescribing information

Special Precautions

Discontinue treatment if there is no improvement in symptoms of angina w/in 3 mth after treatment initiation. Consider treatment discontinuation if there is only limited symptomatic response & when there is no clinically relevant reduction in resting heart rate w/in 3 mth. Caution in patients w/ heart rhythm disorders or sustained atrial fibrillation, or long QT syndrome; symptoms of heart slowing down too much eg, tiredness, dizziness, shortness of breath; symptoms of atrial fibrillation (pulse rate at rest >110 bpm or irregular); recent stroke; mild to moderate low BP; uncontrolled BP; severe heart failure or heart failure w/ bundle branch block; chronic eye retinal disease; moderate liver problems; severe renal problems. Avoid intake of grapefruit juice. Contains lactose; caution in patients w/ intolerance to some sugars. May cause temporary luminous visual phenomena; caution when driving or using machines. Do not give to childn & adolescents <18 yr.

Click to view Bravigo detailed prescribing information

Use In Pregnancy & Lactation

Click to view Bravigo detailed prescribing information

Adverse Reactions

Luminous visual phenomena. Slowing down of heart rate, atrial fibrillation, bradycardia, ventricular extrasystoles, 1st degree AV block, uncontrolled BP, headache, dizziness, blurred vision.

Drug Interactions

Potential interaction w/ fluconazole, rifampicin, barbiturates, phenytoin, St. John's wort, quinidine, disopyramide, ibutilide, sotalol, amiodarone, bepridil, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, IV erythromycin, pentamidine, cisapride, furosemide, hydrochlorothiazide, indapamide. Increased exposure w/ grapefruit juice.

Click to view Bravigo detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Bravigo detailed prescribing information

Storage

View Bravigo storage conditions for details to ensure optimal shelf-life.

Description

View Bravigo description for details of the chemical structure and excipients (inactive components).

Action

View Bravigo mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Anti-Anginal Drugs / Other Cardiovascular Drugs

ATC Classification

C01EB17 - ivabradine ; Belongs to the class of other cardiac preparations.

Regulatory Classification

P₁S₁S₃

Presentation/Packing

Form

Bravigo FC tab 5 mg

Packing/Price

4 × 14's

Form

Bravigo FC tab 7.5 mg

Packing/Price

4 × 14's

Bravigo

ivabradine

Manufacturer:

Genepharm

Distributor:

SB Pharma